stephen silberstein, md, director, jefferson university headache center.
.
.
even though the uk is leaving the eu through brexit, the government may still be under the eu�s environmental jurisdiction, according to the guardian.
.
eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.